Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

Bayer announced the FDA approved finerenone, a nonsteroidal selective mineralocorticoid receptor antagonist, for the ...

Approval of Kerendia was based on results from the Phase III FINEARTS-HF trial, which demonstrated statistically significant ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

Finerenone gained FDA approval for heart failure treatment, showcasing significant benefits in reducing cardiovascular events ...

The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

In a significant move, the U.S. Food and Drug Administration granted approval for Kerendia for patients with heart failure ...

Bayer AG BAYRY announced that the FDA has approved a label expansion of kidney disease drug Kerendia (finerenone). The ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

Alex Gonzalez returns to the pitcher's mound after a lifesaving heart transplant, grateful for the donor who gave him a ...

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic ...